Chlorpheniramine Stats & Data

Harm-reduction points and cautions: 1) First-generation antihistamines have central anticholinergic effects; high doses can cause confusion, agitation, hallucinations, urinary retention, blurred vision, tachycardia, and potentially dangerous hyperthermia. Seek urgent care for severe agitation, delirium, hot/dry skin, or urinary retention. 2) Chlorpheniramine has a long elimination half-life (about 21–27 hours), so next-day drowsiness, slowed reaction time, and impaired coordination may persist beyond the 4–6 hour symptom-relief window; avoid driving or operating machinery if sedated. 3) Do not combine with dextromethorphan-containing ‘CCC/Triple C’ products: chlorpheniramine inhibits the serotonin transporter and is a CYP2D6 inhibitor/substrate; with DXM (a serotonergic CYP2D6 substrate), this raises the risk of serotonin syndrome and delirium. 4) Avoid co-use with MAOIs (or within 14 days of stopping one) due to severe interaction risk, especially if any serotonergic medicine (including DXM) is also present. 5) Additive CNS and respiratory depression occur with alcohol, opioids, benzodiazepines, and other sedatives; if accidental co-use occurs, keep doses low, avoid re-dosing, and ensure a sober monitor. 6) In hot environments or exertion (festivals, clubs), anticholinergic reduction of sweating increases overheating risk; hydrate, rest in shade, and stop use if feeling hot, confused, or unwell. 7) Older adults and those with glaucoma, prostatic hypertrophy/BPH, or a history of urinary retention are more sensitive to anticholinergic effects; consider non-sedating antihistamines instead and consult a clinician. 8) Overdose management is medical: there is no at-home antidote; in hospital, physostigmine may be considered for severe anticholinergic delirium by trained clinicians. 9) Product labels differ; many multi-symptom cold remedies already include chlorpheniramine—avoid double-dosing by checking ‘active ingredients’ on all concurrent OTCs. 10) Clinically significant hepatotoxicity is rare with chlorpheniramine-class drugs, but report unexplained jaundice, dark urine, or right-upper-quadrant pain if they occur after repeated dosing.